JP2018528258A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018528258A5 JP2018528258A5 JP2018521475A JP2018521475A JP2018528258A5 JP 2018528258 A5 JP2018528258 A5 JP 2018528258A5 JP 2018521475 A JP2018521475 A JP 2018521475A JP 2018521475 A JP2018521475 A JP 2018521475A JP 2018528258 A5 JP2018528258 A5 JP 2018528258A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- syndrome
- pharmaceutical composition
- organ
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 239000000427 antigen Substances 0.000 claims 12
- 210000000056 organ Anatomy 0.000 claims 12
- 102000036639 antigens Human genes 0.000 claims 11
- 108091007433 antigens Proteins 0.000 claims 11
- 230000035772 mutation Effects 0.000 claims 11
- 229920001184 polypeptide Polymers 0.000 claims 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 10
- 210000001519 tissue Anatomy 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 9
- 208000011580 syndromic disease Diseases 0.000 claims 9
- 208000023275 Autoimmune disease Diseases 0.000 claims 7
- 229940079593 drug Drugs 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 7
- 230000001939 inductive effect Effects 0.000 claims 7
- 208000006673 asthma Diseases 0.000 claims 6
- 230000002757 inflammatory effect Effects 0.000 claims 6
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 5
- 210000001185 bone marrow Anatomy 0.000 claims 5
- 230000001404 mediated effect Effects 0.000 claims 5
- 206010020751 Hypersensitivity Diseases 0.000 claims 4
- 206010062016 Immunosuppression Diseases 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 210000002865 immune cell Anatomy 0.000 claims 4
- 230000001506 immunosuppresive effect Effects 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 4
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 3
- 206010015150 Erythema Diseases 0.000 claims 3
- 208000007465 Giant cell arteritis Diseases 0.000 claims 3
- 206010018364 Glomerulonephritis Diseases 0.000 claims 3
- 208000015023 Graves' disease Diseases 0.000 claims 3
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 208000011200 Kawasaki disease Diseases 0.000 claims 3
- 241000721454 Pemphigus Species 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 3
- 208000007536 Thrombosis Diseases 0.000 claims 3
- 239000013566 allergen Substances 0.000 claims 3
- 208000026935 allergic disease Diseases 0.000 claims 3
- 230000001363 autoimmune Effects 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 201000001981 dermatomyositis Diseases 0.000 claims 3
- 231100000321 erythema Toxicity 0.000 claims 3
- 208000024908 graft versus host disease Diseases 0.000 claims 3
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 claims 3
- 230000006698 induction Effects 0.000 claims 3
- 206010023332 keratitis Diseases 0.000 claims 3
- 206010025135 lupus erythematosus Diseases 0.000 claims 3
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims 3
- 206010028417 myasthenia gravis Diseases 0.000 claims 3
- 230000002035 prolonged effect Effects 0.000 claims 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 3
- 208000026872 Addison Disease Diseases 0.000 claims 2
- 201000010000 Agranulocytosis Diseases 0.000 claims 2
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 claims 2
- 201000004384 Alopecia Diseases 0.000 claims 2
- 208000023328 Basedow disease Diseases 0.000 claims 2
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims 2
- 241000272201 Columbiformes Species 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 206010012442 Dermatitis contact Diseases 0.000 claims 2
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims 2
- 206010015218 Erythema multiforme Diseases 0.000 claims 2
- 206010015226 Erythema nodosum Diseases 0.000 claims 2
- 206010018687 Granulocytopenia Diseases 0.000 claims 2
- 206010018691 Granuloma Diseases 0.000 claims 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 2
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 claims 2
- 208000031814 IgA Vasculitis Diseases 0.000 claims 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 2
- 208000012528 Juvenile dermatomyositis Diseases 0.000 claims 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 2
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 2
- 206010029240 Neuritis Diseases 0.000 claims 2
- 206010068786 Overlap syndrome Diseases 0.000 claims 2
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims 2
- 206010034277 Pemphigoid Diseases 0.000 claims 2
- 206010036105 Polyneuropathy Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 206010046851 Uveitis Diseases 0.000 claims 2
- 206010047642 Vitiligo Diseases 0.000 claims 2
- 208000002029 allergic contact dermatitis Diseases 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 231100000360 alopecia Toxicity 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 229960000074 biopharmaceutical Drugs 0.000 claims 2
- 201000010415 childhood type dermatomyositis Diseases 0.000 claims 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 2
- 201000004997 drug-induced lupus erythematosus Diseases 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 208000007475 hemolytic anemia Diseases 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 2
- 201000005962 mycosis fungoides Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 206010043207 temporal arteritis Diseases 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 208000010543 22q11.2 deletion syndrome Diseases 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010001881 Alveolar proteinosis Diseases 0.000 claims 1
- 206010001889 Alveolitis Diseases 0.000 claims 1
- 206010001935 American trypanosomiasis Diseases 0.000 claims 1
- 206010002216 Anaphylactoid reaction Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000032467 Aplastic anaemia Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 208000033241 Autosomal dominant hyper-IgE syndrome Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 201000002829 CREST Syndrome Diseases 0.000 claims 1
- 206010062746 Carditis Diseases 0.000 claims 1
- 208000024699 Chagas disease Diseases 0.000 claims 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 1
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 1
- 208000008818 Chronic Mucocutaneous Candidiasis Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 208000011038 Cold agglutinin disease Diseases 0.000 claims 1
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 208000000398 DiGeorge Syndrome Diseases 0.000 claims 1
- 201000003066 Diffuse Scleroderma Diseases 0.000 claims 1
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 claims 1
- 208000021866 Dressler syndrome Diseases 0.000 claims 1
- 201000004315 EAST syndrome Diseases 0.000 claims 1
- 206010014950 Eosinophilia Diseases 0.000 claims 1
- 206010053776 Eosinophilic cellulitis Diseases 0.000 claims 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 claims 1
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000003807 Graves Disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000018565 Hemochromatosis Diseases 0.000 claims 1
- 206010019755 Hepatitis chronic active Diseases 0.000 claims 1
- 206010019860 Hereditary angioedema Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- 206010073257 Idiopathic angioedema Diseases 0.000 claims 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 1
- 206010021263 IgA nephropathy Diseases 0.000 claims 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 1
- 208000023813 IgG4-related thyroid disease Diseases 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- 208000009388 Job Syndrome Diseases 0.000 claims 1
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 claims 1
- 206010024227 Lepromatous leprosy Diseases 0.000 claims 1
- 208000016604 Lyme disease Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims 1
- 206010027910 Mononeuritis Diseases 0.000 claims 1
- 206010028080 Mucocutaneous candidiasis Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000011152 Pemphigus Diseases 0.000 claims 1
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 206010065159 Polychondritis Diseases 0.000 claims 1
- 206010036303 Post streptococcal glomerulonephritis Diseases 0.000 claims 1
- 208000004347 Postpericardiotomy Syndrome Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 206010039705 Scleritis Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000009359 Sezary Syndrome Diseases 0.000 claims 1
- 208000021388 Sezary disease Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims 1
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 claims 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 claims 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 claims 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 201000008736 Systemic mastocytosis Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 208000001106 Takayasu Arteritis Diseases 0.000 claims 1
- 206010043189 Telangiectasia Diseases 0.000 claims 1
- 206010043540 Thromboangiitis obliterans Diseases 0.000 claims 1
- 206010043782 Thyroiditis fibrous chronic Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 241000223109 Trypanosoma cruzi Species 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000025851 Undifferentiated connective tissue disease Diseases 0.000 claims 1
- 208000017379 Undifferentiated connective tissue syndrome Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 206010052568 Urticaria chronic Diseases 0.000 claims 1
- 206010047124 Vasculitis necrotising Diseases 0.000 claims 1
- 208000008526 Wells syndrome Diseases 0.000 claims 1
- 208000006110 Wiskott-Aldrich syndrome Diseases 0.000 claims 1
- 201000005638 acute proliferative glomerulonephritis Diseases 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 230000002052 anaphylactic effect Effects 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 208000010132 annular erythema Diseases 0.000 claims 1
- 206010003230 arteritis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 201000004995 autoimmune glomerulonephritis Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 230000006472 autoimmune response Effects 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 238000010322 bone marrow transplantation Methods 0.000 claims 1
- 208000000594 bullous pemphigoid Diseases 0.000 claims 1
- 238000002659 cell therapy Methods 0.000 claims 1
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000024376 chronic urticaria Diseases 0.000 claims 1
- 206010009869 cold urticaria Diseases 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 201000003278 cryoglobulinemia Diseases 0.000 claims 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 229910003460 diamond Inorganic materials 0.000 claims 1
- 239000010432 diamond Substances 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- 201000008326 granulomatous myositis Diseases 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 230000002949 hemolytic effect Effects 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 208000014796 hyper-IgE recurrent infection syndrome 1 Diseases 0.000 claims 1
- 206010051040 hyper-IgE syndrome Diseases 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 208000021646 inflammation of heart layer Diseases 0.000 claims 1
- 208000001234 inflammatory bowel disease 5 Diseases 0.000 claims 1
- 201000010666 keratoconjunctivitis Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000013734 mononeuritis simplex Diseases 0.000 claims 1
- 201000005518 mononeuropathy Diseases 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 206010033675 panniculitis Diseases 0.000 claims 1
- 208000017262 paroxysmal cold hemoglobinuria Diseases 0.000 claims 1
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 201000006292 polyarteritis nodosa Diseases 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 208000019629 polyneuritis Diseases 0.000 claims 1
- 208000015768 polyposis Diseases 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 208000009169 relapsing polychondritis Diseases 0.000 claims 1
- 206010038796 reticulocytosis Diseases 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 208000009056 telangiectasis Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562192269P | 2015-07-14 | 2015-07-14 | |
| US62/192,269 | 2015-07-14 | ||
| US201562197966P | 2015-07-28 | 2015-07-28 | |
| US62/197,966 | 2015-07-28 | ||
| US201662277201P | 2016-01-11 | 2016-01-11 | |
| US62/277,201 | 2016-01-11 | ||
| PCT/US2016/042074 WO2017011544A1 (en) | 2015-07-14 | 2016-07-13 | Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021003152A Division JP2021063129A (ja) | 2015-07-14 | 2021-01-13 | 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018528258A JP2018528258A (ja) | 2018-09-27 |
| JP2018528258A5 true JP2018528258A5 (enExample) | 2019-08-15 |
| JP6826113B2 JP6826113B2 (ja) | 2021-02-03 |
Family
ID=57757587
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018521475A Active JP6826113B2 (ja) | 2015-07-14 | 2016-07-13 | 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 |
| JP2021003152A Pending JP2021063129A (ja) | 2015-07-14 | 2021-01-13 | 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 |
| JP2023110414A Active JP7605914B2 (ja) | 2015-07-14 | 2023-07-05 | 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 |
| JP2024217195A Pending JP2025038055A (ja) | 2015-07-14 | 2024-12-12 | 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021003152A Pending JP2021063129A (ja) | 2015-07-14 | 2021-01-13 | 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 |
| JP2023110414A Active JP7605914B2 (ja) | 2015-07-14 | 2023-07-05 | 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 |
| JP2024217195A Pending JP2025038055A (ja) | 2015-07-14 | 2024-12-12 | 改良された結合、機能的および安全性特性を有する抗ｃｄ１５４抗体ならびにヒト免疫療法での使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US10874738B2 (enExample) |
| EP (1) | EP3331548A4 (enExample) |
| JP (4) | JP6826113B2 (enExample) |
| KR (2) | KR20250099272A (enExample) |
| CN (2) | CN114671952A (enExample) |
| AU (3) | AU2016294417B2 (enExample) |
| CL (1) | CL2018000103A1 (enExample) |
| CO (1) | CO2018001363A2 (enExample) |
| CR (1) | CR20180097A (enExample) |
| DO (1) | DOP2018000018A (enExample) |
| EA (1) | EA201890297A1 (enExample) |
| EC (1) | ECSP18009949A (enExample) |
| GT (1) | GT201800018A (enExample) |
| HK (1) | HK1249735A1 (enExample) |
| IL (3) | IL310460A (enExample) |
| MX (2) | MX2018000548A (enExample) |
| MY (2) | MY196991A (enExample) |
| PE (1) | PE20180741A1 (enExample) |
| PH (1) | PH12018500098A1 (enExample) |
| SG (1) | SG10201913431QA (enExample) |
| TN (1) | TN2018000021A1 (enExample) |
| WO (1) | WO2017011544A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20180097A (es) * | 2015-07-14 | 2018-05-25 | Immunext Inc | Anticuerpo anti-cd154 con caracteristicas de unión, funcionalidad y seguridad mejoradas y uso en inmunoterapia humana |
| RU2018122255A (ru) | 2015-11-27 | 2019-12-19 | Аблинкс Нв | Полипептиды, ингибирующие cd40l |
| CA3096222A1 (en) | 2018-04-06 | 2019-10-10 | Atyr Pharma, Inc. | Compositions and methods comprising anti-nrp2 antibodies |
| WO2020056162A1 (en) * | 2018-09-12 | 2020-03-19 | Oregon Health & Science University | Detecting and/or subtyping circulating hybrid cells that correlate with stage and survival |
| US20210317220A1 (en) * | 2018-09-24 | 2021-10-14 | Janssen Biotech, Inc. | Method of providing safe administration of an anti-cd154 antibody |
| CN109453383A (zh) * | 2018-11-12 | 2019-03-12 | 陈慧慧 | 免疫检查点的抑制剂在制备治疗青光眼及其他眼部免疫损伤机制相关疾病药物中的应用 |
| CN114173772A (zh) * | 2019-04-12 | 2022-03-11 | 托尼克斯医药控股公司 | Cd40-cd154结合的抑制剂 |
| JP7701913B2 (ja) | 2019-10-03 | 2025-07-02 | エータイアー ファーマ， インコーポレイテッド | 抗ｎｒｐ２抗体を含む組成物および方法 |
| CN113488170B (zh) * | 2021-07-02 | 2023-07-25 | 温州医科大学 | 急性前葡萄膜炎复发风险预测模型构建方法及相关设备 |
| CN117715941A (zh) * | 2021-07-30 | 2024-03-15 | 首尔大学校产学协力团 | 抗cd154抗体及其用途 |
| JP2024527947A (ja) * | 2021-07-30 | 2024-07-26 | ソウル ナショナル ユニバーシティ アールアンドディービー ファウンデーション | 抗ｃｄ１５４抗体及びその用途 |
| WO2024211211A1 (en) | 2023-04-03 | 2024-10-10 | Regeneron Pharmaceuticals, Inc. | Methods of improving transplant survival using il-2 receptor gamma chain antibodies |
| WO2024222895A1 (zh) | 2023-04-28 | 2024-10-31 | 信达生物制药(苏州)有限公司 | 抗cd40l抗体及其在人自身免疫疾病治疗的应用 |
| US20240392022A1 (en) | 2023-05-22 | 2024-11-28 | Genzyme Corporation | Treatment of multiple sclerosis with anti-cd40l antibodies |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ273221A (en) | 1993-09-02 | 2001-09-28 | Dartmouth College | Pharmaceutical for inducing antigen-specific T cell tolerance |
| US6440418B1 (en) | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
| US6001358A (en) * | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
| US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
| US6444018B1 (en) | 1998-06-25 | 2002-09-03 | Xerox Corporation | Phase change ink carrier compositions containing anhydride/amino alcohol-based adducts |
| GB0006398D0 (en) | 2000-03-16 | 2000-05-03 | Novartis Ag | Organic compounds |
| SK5672003A3 (en) * | 2000-10-13 | 2003-10-07 | Biogen Inc | Humanized anti-LT-beta-R antibodies |
| US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
| NZ544486A (en) | 2003-06-13 | 2009-04-30 | Biogen Idec Inc | Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof |
| WO2005018572A2 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
| WO2006104989A2 (en) | 2005-03-29 | 2006-10-05 | Verenium Corporation | Altered antibody fc regions and uses thereof |
| EP2125894B1 (en) * | 2007-03-22 | 2018-12-19 | Biogen MA Inc. | Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof |
| CA2832281C (en) * | 2011-04-04 | 2019-11-05 | Trustees Of Dartmouth College | Anti-cd154 antibodies having impaired fcr binding and/or complement binding properties and the use thereof in immune therapies |
| US9321833B2 (en) * | 2011-04-04 | 2016-04-26 | The Trustees Of Dartmouth College | Methods of therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties |
| CR20180097A (es) * | 2015-07-14 | 2018-05-25 | Immunext Inc | Anticuerpo anti-cd154 con caracteristicas de unión, funcionalidad y seguridad mejoradas y uso en inmunoterapia humana |
-
2016
- 2016-07-13 CR CR20180097A patent/CR20180097A/es unknown
- 2016-07-13 IL IL310460A patent/IL310460A/en unknown
- 2016-07-13 US US15/744,379 patent/US10874738B2/en active Active
- 2016-07-13 MY MYPI2018700104A patent/MY196991A/en unknown
- 2016-07-13 MX MX2018000548A patent/MX2018000548A/es unknown
- 2016-07-13 EP EP16825103.1A patent/EP3331548A4/en active Pending
- 2016-07-13 EA EA201890297A patent/EA201890297A1/ru unknown
- 2016-07-13 HK HK18109202.5A patent/HK1249735A1/zh unknown
- 2016-07-13 IL IL256800A patent/IL256800B2/en unknown
- 2016-07-13 CN CN202210146798.5A patent/CN114671952A/zh active Pending
- 2016-07-13 SG SG10201913431QA patent/SG10201913431QA/en unknown
- 2016-07-13 KR KR1020257020732A patent/KR20250099272A/ko active Pending
- 2016-07-13 MY MYPI2020006781A patent/MY203911A/en unknown
- 2016-07-13 WO PCT/US2016/042074 patent/WO2017011544A1/en not_active Ceased
- 2016-07-13 IL IL297907A patent/IL297907B2/en unknown
- 2016-07-13 TN TNP/2018/000021A patent/TN2018000021A1/en unknown
- 2016-07-13 KR KR1020187004571A patent/KR102825142B1/ko active Active
- 2016-07-13 PE PE2018000072A patent/PE20180741A1/es unknown
- 2016-07-13 JP JP2018521475A patent/JP6826113B2/ja active Active
- 2016-07-13 AU AU2016294417A patent/AU2016294417B2/en active Active
- 2016-07-13 CN CN201680053004.3A patent/CN108135969B/zh active Active
-
2018
- 2018-01-11 PH PH12018500098A patent/PH12018500098A1/en unknown
- 2018-01-12 MX MX2023014921A patent/MX2023014921A/es unknown
- 2018-01-12 DO DO2018000018A patent/DOP2018000018A/es unknown
- 2018-01-12 GT GT201800018A patent/GT201800018A/es unknown
- 2018-01-12 CL CL2018000103A patent/CL2018000103A1/es unknown
- 2018-02-09 EC ECIEPI20189949A patent/ECSP18009949A/es unknown
- 2018-02-12 CO CONC2018/0001363A patent/CO2018001363A2/es unknown
-
2020
- 2020-11-23 US US17/101,139 patent/US11596689B2/en active Active
-
2021
- 2021-01-13 JP JP2021003152A patent/JP2021063129A/ja active Pending
-
2022
- 2022-11-02 AU AU2022263520A patent/AU2022263520B2/en active Active
-
2023
- 2023-02-01 US US18/162,769 patent/US20240000929A1/en active Pending
- 2023-07-05 JP JP2023110414A patent/JP7605914B2/ja active Active
-
2024
- 2024-12-12 JP JP2024217195A patent/JP2025038055A/ja active Pending
-
2025
- 2025-09-05 AU AU2025226796A patent/AU2025226796A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018528258A5 (enExample) | ||
| US7169389B2 (en) | Human CD154 binding molecules and treatment methods | |
| TWI889694B (zh) | 介白素-2藥劑及其用途 | |
| JP7267921B2 (ja) | プログラム細胞死（ｐｄ－１）に対するシングルドメイン抗体 | |
| US20080227704A1 (en) | CXCL13 binding proteins | |
| TWI496790B (zh) | 介白素-１３結合蛋白質 | |
| AU2013206788B2 (en) | Method of providing monoclonal auto-antibodies with desired specificity | |
| AU2001248350A1 (en) | Antibodies to human CD154 | |
| JP2014516945A5 (enExample) | ||
| JP2011520898A5 (enExample) | ||
| CN108367075A (zh) | 4-1bb结合蛋白及其用途 | |
| JP2020073499A (ja) | インターフェロンアルファ及びオメガ抗体アンタゴニスト | |
| JP2016527187A5 (enExample) | ||
| JP2013500721A5 (enExample) | ||
| JP2015504419A (ja) | Ｔ細胞反応の選択的阻害のための抗体および方法 | |
| WO2011163478A4 (en) | Dual variable domain immunoglobulins and uses thereof | |
| BR112013012396A2 (pt) | anticorpos anti-ccl20 de neutralização | |
| HK1207870A1 (en) | Anti-human sema4a antibodies useful to treat disease | |
| Stirling et al. | Future treatments of allergic diseases and asthma | |
| JPWO2020208177A5 (enExample) | ||
| JP2023514224A (ja) | 自己免疫障害における抗ｂｃｍａ治療 | |
| NZ739859A (en) | Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy | |
| NZ739859B2 (en) | Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy | |
| US12146160B2 (en) | Regulatory T cells targeted by lymphotoxin alpha blocking agent and uses thereof | |
| TH2101002815A (th) | โมโนโคลนอลแอนติบอดีที่เป็นแอนทาโกนิสท์ต่อ cd40 และการใช้แอนติบอดีดังกล่าว |